To everyone interested in open access science, and in the acceleration of biomedical research and cures for disease, please spread the following message.
Attention philanthropists: you have a unique and fleeting opportunity to establish the largest publicly available genetic and biomedical dataset in the world, and to greatly accelerate the race to cures for many diseases.
The data belong to the company 23andMe. CEO Anne Wojcicki, and a private equity group, New Mountain Capital, are proposing to take the company private, along with genetic and other data of 14 million customers (about 11M of whom have accompanying trait/biomedical survey data). There is enormous unrealized value in the 23andMe data and making it publicly available/open access would represent an unprecedented contribution to biomedical research; but, again, time is of the essence. On January 28 the company announced that they were open to acquisition, and then on Friday, February 22nd the offer from New Mountain Capital was announced. The proposal awaits review and a vote by the three members of the 23andMe board of directors.
The current $74.7M offer to take 23andMe private assigns a value of just over $5 per customer dataset. In contrast, I estimate that costs to acquire, analyze, report, and store all customers genetic and other data exceed $1 billion. Even if newer and superior methods for DNA analysis were employed, sample acquisition and data storage costs alone would be substantially in excess of the current offer for the company. The kind of data held by 23andMe are still widely used and valuable, especially if the number of datasets is in the millions. These data would provide a starting foundation for building a biomedical discovery infrastructure of enormous and unparalleled value.
A visionary and compassionate philanthropist should acquire 23andMe and make as much of the data publicly available as possible. Here is one possible model: existing 23andMe customers could be re-consented, ideally for public sharing/open access of their genetic and phenotype data. The data of those who do not consent to public sharing could still be used for research, and access to these data could be managed through an application process, similar to the UK BioBank model. Free and open access to even 10% of the 23andMe data would establish the largest such dataset in the world, which would be a game changer in biomedical research, helping to accelerate cures for many diseases. Please DM
@PrestonWEstep if you have a serious interest; I am happy to contribute to a detailed analysis and proposal.